Ionis gets FDA breakthrough therapy status for angelman syndrome drug

6 hours ago 1

Ionis Pharmaceuticals (NASDAQ:IONS) said on Tuesday that the U.S. FDA has granted breakthrough therapy status to its antisense medicine, ION582, for the treatment of angelman syndrome, a neurological disease.
This designation is based on results from a trial of ION582